EMBC — Embecta Corp
NASDAQ · Healthcare · Medical Instruments & Supplies
$5.50
+$0.25 (+4.86%)
Embecta Corp (EMBC) is a medical instruments & supplies company listed on NASDAQ. It is led by Devdatt Kurdikar Ph.D., based in 300 Kimball Drive, Parsippany, NJ, United States, 07054, with about 2,000 employees. Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. It primarily sells its products to wholesalers and distributors. The company was formerly known as Berra Newco, Inc. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.
Latest reported EMBC revenue for 2025-09-30 was $1.08B. Net income was $95.4M. Revenue was up 265.6% from 2025-06-30 to 2025-09-30. EMBC currently screens at market cap $609.6M and trailing P/E 11.7.
Use this EMBC page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the EMBC quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the EMBC SEC filings page. Lician reads the product cache first so this HTML stays unique to Embecta Corp even when a live quote feed is slow.
About Embecta Corp
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. It primarily sells its products to wholesalers and distributors. The company was formerly known as Berra Newco, Inc. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.
EMBC Key Statistics
Market Cap
$609.56M
Volume
1.29M
Previous Close
$4.99
Day Range
$4.88 – $5.04
P/E Ratio
11.72
EPS
$1.62
Revenue
$1.08B
Net Income
$95.40M
Gross Profit
$0.00
Free Cash Flow
$0.00
Dividend Yield
6.20%
Revenue Growth
-3.8%
Profit Margin
8.8%
Employees
2,000
EMBC Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $1.08B | $1.12B | $1.12B | $1.13B |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | $95.40M | $78.30M | $70.40M | $223.60M |
| EPS (Diluted) | $1.62 | $1.34 | $1.22 | $3.89 |
Total Assets
$1.09B
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$225.50M
Operating Cash Flow
$191.70M
Free Cash Flow
$0.00
Embecta Corp Company Information
- President, CEO & Director
- Devdatt Kurdikar Ph.D.
- Headquarters
- 300 Kimball Drive, Parsippany, NJ, United States, 07054
- Website
- www.embecta.com
- Phone
- 862 401 0000
- IPO / Founded
- 2022-04-01
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies